2,6-Dimethylpiperidin-4-ol hydrochloride | 179175-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,6-Dimethylpiperidin-4-ol hydrochloride
• 英文别名: 2,6-dimethylpiperidin-4-ol;hydrochloride
• CAS: 179175-18-9
• 化学式: C7H16ClNO
• 分子量: 165.66
• InChiKey: IJIHNPOPPHLAHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Rho kinase inhibitors
  申请人：——

  公开号：US20040138286A1

  公开（公告）日：2004-07-15

  A compound represented by the formula (1): 1 wherein R 1 —X— indicates that 1 to 4 R 1 —X— groups are present which may be the same or different, the ring A is a saturated or unsaturated 5-membered heterocyclic ring, X is a single bond, a group represented by the formula: —N(R 3 )—, —O— or —S—, or the like. R 1 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, R 2 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, and R 3 is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like; a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.

  化合物的化学式为（1）：1，其中R1—X—表示存在1到4个R1—X—基团，可以相同也可以不同，环A是饱和或不饱和的5元杂环，X是单键，一个由式子表示的基团：—N（R3）—，—O—或—S—等。R1是氢原子，卤素原子，硝基，羧基，取代或未取代的烷基或类似物，R2是氢原子，卤素原子，硝基，羧基，取代或未取代的烷基或类似物，R3是氢原子，取代或未取代的烷基或类似物；该化合物的前药或药物可接受的盐是治疗Rho激酶相关疾病的有用化合物。
• TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0790247A1

  公开（公告）日：1997-08-20

  The present invention relates to a tetrahydroisoquinoline derivative represented by the following formula 1 exhibiting an inhibitory action for agglutination caused by fibrinogen, which may be effectively used as an antithrombotic agent or a platelet agglutination-inhibiting agent. The present invention also relates to a medical preparation containing such compound. In formula 1, B and G are an alkylene optionally substituted with an alkyl or the like; D is H, an alkyl, or the like; E is 1,2,3,4-tetrahydroisoquinoline optionally substituted with R1 to R4 which binds to G at position 2; R1 to R4 are an alkyl or the like; L is hydroxy or the like; and A is a substituent represented by formula (2), and C is carbon. In formula 2, M and R5 to R8 are H, an alkyl or the like.

  本发明涉及一种由下式 1 表示的四氢异喹啉衍生物，该衍生物对纤维蛋白原引起的凝集具有抑制作用，可有效用作抗血栓剂或血小板凝集抑制剂。本发明还涉及一种含有此类化合物的医疗制剂。 在式 1 中，B 和 G 是任选被烷基或类似物取代的亚烷基；D 是 H、烷基或类似物；E 是任选被 R1 至 R4 取代的 1，2，3，4-四氢异喹啉，它在第 2 位与 G 结合；R1 至 R4 是烷基或类似物；L 是羟基或类似物；A 是式 (2) 所代表的取代基，C 是碳。 在式 2 中，M 和 R5 至 R8 是 H、烷基或类似物。
• Rho KINASE INHIBITORS
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1403255A1

  公开（公告）日：2004-03-31

  A compound represented by the formula (1): wherein R1-X- indicates that 1 to 4 R1-X- groups are present which may be the same or different,    the ring A is a saturated or unsaturated 5-membered heterocyclic ring,    X is a single bond, a group represented by the formula: -N(R3)-, -O- or -S-, or the like.    R1 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like,    R2 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, and    R3 is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like; a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.

  由式（1）代表的化合物： 其中 R1-X- 表示存在 1 至 4 个 R1-X- 基团，这些基团可以相同或不同、 环 A 是饱和或不饱和的五元杂环、 X 是单键、由式子表示的基团：-N(R3)-、-O- 或 -S- 或类似的基团。 R1 是氢原子、卤素原子、硝基、羧基、取代或未取代的烷基或类似基团、 R2 是氢原子、卤素原子、硝基、羧基、取代或未取代的烷基或类似物，以及 R3 是氢原子、取代或未取代的烷基或类似物； 所述化合物的原药或所述化合物或原药的药学上可接受的盐是一种有用的化合物，可作为治疗 Rho 激酶引起的疾病的药物。
• US5789595A
  申请人：——

  公开号：US5789595A

  公开（公告）日：1998-08-04
• US7199147B2
  申请人：——

  公开号：US7199147B2

  公开（公告）日：2007-04-03